Ercros
ECR.MC
| Exchange: | MC |
| Currency | Euro |
| ISIN: | ES0125140A14 |
| LEI: | 959800Z611RK76NEVF32 |
| Primary Ticker: | ECR.MC |
| Fiscal Year End: | December |
| International Domestic: | International |
| Sector: | Basic Materials |
| Industry: | Chemicals |
| Gic Sector: | Materials |
| Gic Group: | Materials |
| Gic Industry: | Chemicals |
| Gic Sub Industry: | Commodity Chemicals |
| Description: | Ercros, S.A. manufactures and sells basic chemicals, intermediate chemicals, and pharmaceuticals in Spain. It operates through three segments: Chlorine Derivatives, Intermediate Chemicals, and Pharmacy. The Chlorine Derivatives segment produces ammonia, bioplastics, caustic potash and soda, chlorine, chloroisocyanurates, dicalcium phosphate, dichloroethane, hydrochloric acid, hydrogen peroxide, potassium carbonate, PVC compounds, sodium chlorate and chlorite, sodium hypochlorite, and vinyl chloride monomers and polychloride. This segment's products are used as intermediates in other industrial processes to purify and treat drinking and waste water; treat and maintain swimming pool water; bleach fabrics and paper; produce solvents, detergents, and strippers; manufacture printing inks and coloring; to produce compound feed and in cooling equipment. The Intermediate Chemicals segment provides formaldehyde, glues and resins, molding compunds, paraformaldehyde, pentaerythritol and dipentaerythritol, and sodium formate for manufacturing of particle, and decorative laminates and plywoods, as well as resins, paints, and varnishes in the furniture and decoration industry; sockets and switches in the electrical components sector; and tableware, and health and packaging items in the textile tanning industry. The Pharmacy division engages in the production of raw materials and pharmaceutical intermediate products from antibiotic, cholesterol-lowering, anti-ulcer, and anti-fungal agents. This segment's products include amlodipine besylate, azithromycin, clarithromycin, erythromycins, famotidine, fosfomycin calcium and sodium, fosfomycin trometamol, and fusidic acid. The company is also involved in exporting activities. Ercros, S.A. was founded in 1817 and is headquartered in Barcelona, Spain. |
| Address: | Avinguda Diagonal, 593-595, Barcelona, Spain, 08014 |
| Website: | https://www.ercros.es |
| Full Time Employees: | 1359 |
| Updated On: | 2024-11-05 |
Highlights
| Market Capitalization: | 329627488 |
| Market Capitalization Mln: | 329.62 |
| EBITDA: | 1350000 |
| PE Ratio: | 25.75 |
| PEG Ratio: | 0.32 |
| Wall Street Target Price: | 0.76 |
| Book Value: | 3.88 |
| Dividend Share: | 0.09 |
| Dividend Yield: | 0.02 |
| Earnings Share: | 0.14 |
| EPS Estimate Current Year: | 0.67 |
| EPS Estimate Next Year: | 0.4 |
| Most Recent Quarter: | 2024-06-30 |
| Profit Margin: | 0.01 |
| Operating Margin TTM: | 0.02 |
| Return On Assets TTM: | -0.01 |
| Return On Equity TTM: | 0.03 |
| Revenue TTM: | 657222976 |
| Revenue Per Share TTM: | 7.22 |
| Quarterly Revenue Growth YOY: | -0.15 |
| Gross Profit TTM: | 311141000 |
| Diluted Eps TTM: | 0.14 |
| Quarterly Earnings Growth YOY: | -0.19 |
Valuation
| Trailing PE: | 25.75 |
| Forward PE: | 14.43 |
| Price Sales TTM: | 0.50 |
| Price Book MRQ: | 0.92 |
| Enterprise Value: | 446714678 |
| Enterprise Value Revenue: | 0.69 |
| Enterprise Value Ebitda: | 20.58 |
Shares
| Shares Outstanding: | 91436200 |
| Shares Float: | 77066086 |
| Percent Insiders: | 15.82 |
| Percent Institutions: | 11.84 |
Technicals
| Beta: | 0.75 |
| 52 Week High: | 3.96 |
| 52 Week Low: | 2.21 |
| 50 Day MA: | 3.67 |
| 200 Day MA: | 3.46 |
Splits & Dividends
| Forward Annual Dividend Rate: | 0.1 |
| Forward Annual Dividend Yield: | 0.02 |
| Ex Dividend Date: | 2024-07-08 |
| Last Split Factor: | 1:10 |
| Last Split Date: | 2009-10-12 |
Earnings
| Report Date: | 2025-04-28 |
| Date: | 2025-03-31 |
| Before After Market: | After Market |
| Currency: | EUR |
| Report Date: | 2025-02-25 |
| Date: | 2024-12-31 |
| Before After Market: | After Market |
| Currency: | EUR |
| Report Date: | 2024-11-15 |
| Date: | 2024-09-30 |
| Before After Market: | After Market |
| Currency: | EUR |
| Report Date: | 2016-03-31 |
| Date: | 2016-03-31 |
| Currency: | EUR |
| Eps Actual: | 0.06 |
| Report Date: | 2015-12-31 |
| Date: | 2015-12-31 |
| Currency: | EUR |
| Eps Actual: | 0.01 |
| Report Date: | 2015-09-30 |
| Date: | 2015-09-30 |
| Currency: | EUR |
| Report Date: | 2015-06-30 |
| Date: | 2015-06-30 |
| Currency: | EUR |
| Eps Actual: | 0.04 |
| Report Date: | 2015-03-31 |
| Date: | 2015-03-31 |
| Currency: | EUR |
| Report Date: | 2014-12-31 |
| Date: | 2014-12-31 |
| Currency: | EUR |
| Eps Actual: | -0.08 |
| Report Date: | 2014-09-30 |
| Date: | 2014-09-30 |
| Currency: | EUR |
| Report Date: | 2014-06-30 |
| Date: | 2014-06-30 |
| Currency: | EUR |
| Eps Actual: | 0.04 |
| Report Date: | 2014-03-31 |
| Date: | 2014-03-31 |
| Currency: | EUR |
| Eps Actual: | -0.02 |
| Report Date: | 2013-12-31 |
| Date: | 2013-12-31 |
| Currency: | EUR |
| Eps Actual: | -0.00 |
| Report Date: | 2013-09-30 |
| Date: | 2013-09-30 |
| Currency: | EUR |
| Report Date: | 2013-06-30 |
| Date: | 2013-06-30 |
| Currency: | EUR |
| Eps Actual: | 0.03 |
| Report Date: | 2013-03-31 |
| Date: | 2013-03-31 |
| Currency: | EUR |
| Eps Actual: | -0.07 |
| Report Date: | 2012-12-31 |
| Date: | 2012-12-31 |
| Currency: | EUR |
| Eps Actual: | -0.03 |
| Report Date: | 2012-06-30 |
| Date: | 2012-06-30 |
| Currency: | EUR |
| Report Date: | 2012-03-31 |
| Date: | 2012-03-31 |
| Currency: | EUR |
| Eps Actual: | -0.05 |
| Report Date: | 2011-12-31 |
| Date: | 2011-12-31 |
| Currency: | EUR |
| Eps Actual: | -0.04 |
| Report Date: | 2011-09-30 |
| Date: | 2011-09-30 |
| Currency: | EUR |
| Eps Actual: | -0.01 |
| Report Date: | 2011-06-30 |
| Date: | 2011-06-30 |
| Currency: | EUR |
| Eps Actual: | 0.03 |
| Report Date: | 2011-03-31 |
| Date: | 2011-03-31 |
| Currency: | EUR |
| Eps Actual: | 0.02 |
| Report Date: | 2010-12-31 |
| Date: | 2010-12-31 |
| Currency: | EUR |
| Eps Actual: | -0.01 |
| Report Date: | 2010-09-30 |
| Date: | 2010-09-30 |
| Currency: | EUR |
| Eps Actual: | -0.01 |
| Report Date: | 2010-06-30 |
| Date: | 2010-06-30 |
| Currency: | EUR |
| Eps Actual: | -0.02 |
| Report Date: | 2010-03-31 |
| Date: | 2010-03-31 |
| Currency: | EUR |
| Eps Actual: | -0.07 |
| Report Date: | 2009-12-31 |
| Date: | 2009-12-31 |
| Currency: | EUR |
| Eps Actual: | -0.11 |
| Report Date: | 2009-09-30 |
| Date: | 2009-09-30 |
| Currency: | EUR |
| Eps Actual: | -0.19 |
| Report Date: | 2009-06-30 |
| Date: | 2009-06-30 |
| Currency: | EUR |
| Eps Actual: | -0.10 |
| Report Date: | 2009-03-31 |
| Date: | 2009-03-31 |
| Currency: | EUR |
| Eps Actual: | -0.07 |
| Date: | 2023-12-31 |
| Period: | +1y |
| Growth: | -0.40 |
| Earnings Estimate Avg: | 0.40 |
| Earnings Estimate Low: | 0.40 |
| Earnings Estimate High: | 0.40 |
| Earnings Estimate Year Ago Eps: | 0.67 |
| Earnings Estimate Number Of Analysts: | 1.00 |
| Earnings Estimate Growth: | -0.40 |
| Revenue Estimate Avg: | 847800000.00 |
| Revenue Estimate Low: | 847800000.00 |
| Revenue Estimate High: | 847800000.00 |
| Revenue Estimate Number Of Analysts: | 1.00 |
| Revenue Estimate Growth: | -0.18 |
| Eps Trend Current: | 0.40 |
| Eps Trend7days Ago: | 0.45 |
| Eps Trend30days Ago: | 0.45 |
| Eps Trend60days Ago: | 0.45 |
| Eps Trend90days Ago: | 0.51 |
| Eps Revisions Down Last30days: | 1.00 |
| Date: | 2022-12-31 |
| Growth: | 0.55 |
| Earnings Estimate Avg: | 0.67 |
| Earnings Estimate Low: | 0.67 |
| Earnings Estimate High: | 0.67 |
| Earnings Estimate Year Ago Eps: | 0.43 |
| Earnings Estimate Number Of Analysts: | 1.00 |
| Earnings Estimate Growth: | 0.55 |
| Revenue Estimate Avg: | 1035400000.00 |
| Revenue Estimate Low: | 1035400000.00 |
| Revenue Estimate High: | 1035400000.00 |
| Revenue Estimate Number Of Analysts: | 1.00 |
| Revenue Estimate Growth: | 0.29 |
| Eps Trend Current: | 0.67 |
| Eps Trend7days Ago: | 0.66 |
| Eps Trend30days Ago: | 0.66 |
| Eps Trend60days Ago: | 0.66 |
| Eps Trend90days Ago: | 0.72 |
| Eps Revisions Up Last7days: | 1.00 |
| Eps Revisions Up Last30days: | 1.00 |
| Date: | 2022-09-30 |
| Revenue Estimate Avg: | 271159000.00 |
| Revenue Estimate Growth: | 0.36 |
| Date: | 2022-06-30 |
| Revenue Estimate Avg: | 284171000.00 |
| Revenue Estimate Growth: | 0.42 |
| Date: | 2022-03-31 |
| Revenue Estimate Avg: | 266470000.00 |
| Date: | 2021-12-31 |
| Revenue Estimate Avg: | 728700000.00 |
| Revenue Estimate Low: | 728700000.00 |
| Revenue Estimate High: | 728700000.00 |
| Revenue Estimate Number Of Analysts: | 1.00 |
| Revenue Estimate Growth: | -0.08 |
| Date: | 2019-12-31 |
| Period: | +1y |
| Revenue Estimate Avg: | 599280000.00 |
| Revenue Estimate Low: | 599280000.00 |
| Revenue Estimate High: | 599280000.00 |
| Revenue Estimate Number Of Analysts: | 1.00 |
| Revenue Estimate Growth: | 0.02 |
| Eps Trend7days Ago: | 0.15 |
| Eps Trend30days Ago: | 0.15 |
| Eps Trend60days Ago: | 0.15 |
| Eps Trend90days Ago: | 0.15 |
| Date: | 2019-06-30 |
| Period: | +1q |
| Revenue Estimate Avg: | 587530000.00 |
| Revenue Estimate Low: | 587530000.00 |
| Revenue Estimate High: | 587530000.00 |
| Revenue Estimate Number Of Analysts: | 1.00 |
| Date: | 2019-03-31 |
| Revenue Estimate Avg: | 587530000.00 |
| Revenue Estimate Low: | 587530000.00 |
| Revenue Estimate High: | 587530000.00 |
| Revenue Estimate Number Of Analysts: | 1.00 |
| Date: | 2018-12-31 |
| Revenue Estimate Avg: | 587530000.00 |
| Revenue Estimate Low: | 587530000.00 |
| Revenue Estimate High: | 587530000.00 |
| Revenue Estimate Number Of Analysts: | 1.00 |
| Eps Trend7days Ago: | 0.10 |
| Eps Trend30days Ago: | 0.10 |
| Eps Trend60days Ago: | 0.10 |
| Eps Trend90days Ago: | 0.10 |
| Date: | 2024-09-30 |
| Eps Actual: | 0.06 |
| Date: | 2015-12-31 |
| Eps Actual: | 0.06 |
| Date: | 2014-12-31 |
| Eps Actual: | -0.05 |
| Date: | 2013-12-31 |
| Eps Actual: | -0.03 |
| Date: | 2012-12-31 |
| Eps Actual: | -0.09 |
| Date: | 2011-12-31 |
| Eps Actual: | -0.00 |
| Date: | 2010-12-31 |
| Eps Actual: | -0.12 |
| Date: | 2009-12-31 |
| Eps Actual: | -0.49 |